Introduction {#s0001}
============

Lung cancer is the most common cause of cancer mortality globally. In 2013, the estimated global lung cancer incidence was 1.8 million, and the estimated number of fatal cases was 1.6 million.[@cit0001] According to the Korean National Lung Cancer registry data, the crude incidence rate of lung cancer was 43.9 per 100,000, and the age-standardized mortality rate was 19.8 per 100,000 in 2012.[@cit0002],[@cit0003] Adenocarcinoma is the most frequent histologic subtype, and it accounts for 50% of all lung cancers.[@cit0004] Although new treatment modalities, including molecular-targeted therapy and immune checkpoint inhibitors, have demonstrated remarkable survival benefits in patients with advanced lung adenocarcinoma,[@cit0004],[@cit0005] the prognosis is still poor, and more individualized therapeutic strategies should be established to improve clinical outcomes.

^18^F-fluorodeoxyglucose positron emission tomography-computed tomography (^18^F-FDG PET/CT) is a functional imaging modality that measures the glucose metabolism of tumors. Due to its advantages over conventional techniques such as CT scan, it is widely used in lung cancer management; its uses include staging at diagnosis, response evaluation after systemic treatment, re-staging after neoadjuvant treatment, and surveillance after curative resection or stereotactic radiosurgery.[@cit0006],[@cit0007] To extend its application in practice, numerous studies have evaluated the possible utility of the semi-quantitative metabolic parameters obtained from ^18^F-FDG PET/CT images. Standardized uptake value (SUV) is the most widely investigated across various human malignancies; some studies reported the association between maximal SUV (SUVmax) and poor survival of non-small-cell lung carcinoma (NSCLC) patients,[@cit0008]--[@cit0010] while others showed no association.[@cit0011]--[@cit0014] These conflicting data partially result from the limitation of SUVmax; it is vulnerable to statistical noise, as it is measured using a single voxel analysis.[@cit0015] Thus, recent studies have focused on the volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), which reflect metabolic tumor burden.

Most of the studies that have evaluated the prognostic values of the volumetric parameters were conducted on early-stage, operable NSCLC. According to a meta-analysis, high SUVmax, MTV, and TLG were significantly associated with a high risk of recurrence and death in patients who received surgical resection.[@cit0010] However, studies on the clinical utility of those parameters in advanced diseases are rare, and only 3 studies have been reported to date.[@cit0012],[@cit0016],[@cit0017] One study reported that high whole-body MTV and TLG, rather than SUVmax, were associated with poor survival in stage IV NSCLC, suggesting that global metabolic tumor burden is associated with prognosis.[@cit0016] In contrast, the two other studies simultaneously evaluated MTV and TLG from whole-body and primary tumors and reported that the MTV of a primary tumor was independently associated with progression-free survival (PFS)[@cit0017] and overall survival (OS).[@cit0012],[@cit0017] The latter suggests the prognostic utility of the volumetric parameters measured in primary tumors, not in all the target lesions, even in advanced NSCLC.

*EGFR* mutations are major driver mutations occurring in lung adenocarcinomas.[@cit0018] Approximately 15% of Caucasian and 30%--40% of Asian patients with lung adenocarcinoma have tumors with *EGFR* mutations.[@cit0019] Although these patients have shown prolonged PFS when treated with *EGFR*-tyrosine kinase inhibitors (TKIs), the response rate is no more than 70%--80%, and resistance inevitably occurs after approximately 11 months of treatment in most patients.[@cit0020]--[@cit0022] Thus, it is important to determine predictive and prognostic factors before TKI treatment to improve clinical outcomes.

To address this issue, we conducted this study to determine whether metabolic parameters of ^18^F-FDG PET/CT can discriminate between *EGFR-*mutated lung adenocarcinomas and *EGFR* wild-types and predict treatment response and survival in patients treated with first-line *EGFR*-TKIs.

Patients and Methods {#s0002}
====================

Study Subjects and Data Collection {#s0002-s2001}
----------------------------------

We retrospectively recruited patients who received systemic treatment for histologically confirmed, locally advanced, or metastatic lung adenocarcinoma at the Kyung Hee University Hospital, a tertiary referral hospital in South Korea, between March 2016 and November 2019. Patients who did not have available follow-up data, initial ^18^F-FDG PET/CT images, a history of other cancers, other driving genetic alterations including *ROS1* and *ALK* fusions, and previous history of chemotherapy or radiotherapy were excluded. *EGFR*-negative patients were all treated with pemetrexed/platinum doublet with or without pemetrexed continuation maintenance chemotherapy, while *EGFR*-mutant patients were treated with *EGFR*-TKIs, including gefitinib, erlotinib, or afatinib as a first-line treatment.

All patients underwent staging workup, including chest computed tomography (CT), brain magnetic resonance imaging, and ^18^F-FDG PET/CT. TNM staging was performed according to the 8^th^ edition of the International Association for the Study of Lung Cancer TNM staging system.[@cit0023] Tumor response was examined by CT after every two cycles of systemic treatment and evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.[@cit0024] For *EGFR*-TKIs, a single cycle comprised 4 weeks of treatment. We reviewed electronic medical records to obtain demographic information, past medical or social history, and clinical data of all participants. This study protocol was approved by the Clinical Research Ethics Committee of the Kyung Hee University Hospital (KHUH2020-03-088), and written informed consent was obtained from all patients who were alive, but it was waived for patients who had died. All research was carried out in compliance with the Declaration of Helsinki.

*EGFR* Mutation Testing {#s0002-s2002}
-----------------------

All the *EGFR* tests were performed using the tumor tissues. Genomic DNA was extracted from formalin-fixed, paraffin-embedded, 5-µm-thick tissue sections using the High Pure Template Preparation Kit (Roche Applied Science, Mannheim, Germany). The extracted DNA was stored at −20°C until analysis. EGFR Pyro Kit (QIAGEN Korea Ltd., Seoul, Korea) and PyroMark Q24 System (QIAGEN Korea Ltd., Seoul, Korea) were used to detect *EGFR* mutations by real-time polymerization chain reaction (PCR). The primer sets covered mutations or deletions spanning exons 18 to 21 of the genes encoding the tyrosine kinase domain of *EGFR*. The results were interpreted according to the manufacturer's instructions.

Acquisition of PET/CT Images and Calculation of Metabolic Parameters {#s0002-s2003}
--------------------------------------------------------------------

All patients underwent PET/CT scanning with Gemini TF16 PET/CT scanners (Philips Medical Systems, Cleveland, OH) before the initiation of systemic treatment. After fasting for at least 6 hours, 5--6 MBq/kg of ^18^F-FDG was administered intravenously, and scanning was performed after 60 minutes. Low-dose unenhanced CT scans were first obtained for attenuation correction, and then PET scans (1 min per bed) were obtained. The values of the metabolic parameters were assessed by two experienced nuclear medicine physicians (I.K.H and C.K) using MIRADA XD3 software (MIRADA Medical, Oxford, UK). Physicians dragged the cursor from the center of the primary tumor to a point near the edge of the lesion, and the software automatically outlined a three-dimensional volume of interest (VOI) on the tumor. MTV and TLG were calculated using two SUV cutoff values of 1.5 and 2.5 for this semi-automated contouring system to exclude physiologic FDG uptake of the non-tumor tissue. MTV was defined as the total tumor volume inside the boundaries of the VOI. TLG was calculated as the product of MTV and the mean SUV of the lesion.

Statistical Analyses {#s0002-s2004}
--------------------

Baseline characteristics between groups were compared using Fisher's exact test. The optimal cutoff for SUVmax for the discrimination of *EGFR* mutation was identified using receiver operating characteristic (ROC) curve analysis. The optimal cutoff values of SUVmax, MTV, and TLG for survival analysis were defined using the point with the lowest *p*-value on the Log rank test for progression-free survival (PFS) for all possible values of each parameter. PFS and OS were defined as the periods from the first day of treatment to disease progression/death and death from any cause, respectively. Data on patients without tumor recurrence or death were censored at the last follow-up. Associations between clinical parameters and *EGFR* mutational status or survival were evaluated by univariate analysis using the Log rank test, and subsequently, the multivariate Cox's proportional hazard regression was conducted with adjustment for parameters with *p-*values \< 0.3 from the univariate analysis. Survival curves were generated using the Kaplan--Meier method. *P*-values \< 0.05 were considered significant. All analyses were performed using SPSS version 20.0 (IBM Corporation, Armonk, NY, USA) and MedCalc (MedCalc Software Ltd, Ostend, Belgium).

Results {#s0003}
=======

Patient Characteristics {#s0003-s2001}
-----------------------

During the study period, 372 patients were newly diagnosed with NSCLC. Of them, 160 underwent first-line treatment with platinum-based doublet for those without *EGFR* mutation or *EGFR*-TKIs for those with *EGFR* mutation. Eleven patients who had only external ^18^F-FDG PET/CT images, 5 without unavailable survival data, 3 with history of other cancers, 4 with genetic alterations other than *EGFR* mutation, and 3 who received other cancer treatments were excluded. Finally, a total of 134 (72 *EGFR*-negative and 62 *EGFR*-positive) patients were eligible for analysis.

The clinical characteristics of the study population are summarized in [Table 1](#t0001){ref-type="table"}. All subjects were Korean, and their median age was 69 years (range, 39--81 years). Forty-five (34%) patients were female. Sixty-seven (50%) patients were aged ≥ 65 years. Seventy-six (57%) patients were current or former smokers. One hundred and eight (80%) patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Nine (7%) patients had stage IIIB, and 125 (93%) patients had stage IV. Twenty-eight (20%) patients had metastases at \> 3 organs. Thirty-nine (29%) and 22 (16%) patients had brain and liver metastasis, respectively. Thirty-five (57%) patients had exon 19 deletions, 25 (47%) patients had L858R point mutations, and 2 patients had uncommon mutations (G719X and S768I, respectively) among *EGFR-*mutated patients. Compared with *EGFR*-negative patients, the proportions of females (52% vs 18%, *p* = 0.046) and those who had never smoked (61% vs 28%, *p* = 0.017) were higher in the *EGFR-*mutated group.Table 1Characteristics of Patients with Advanced Lung AdenocarcinomasNo. of Patients (%)*EGFR* Mutational Status*p* valueNegativePositiveAll134 (100)72 (54)62 (46)Gender0.046 Female45 (34)13 (18)32 (52) Male89 (66)59 (82)30 (47)Age, yrs0.883 \<6567 (50)39 (54)28 (45) ≥6567 (50)33 (46)34 (55)Smoking0.017 Never58 (43)20 (28)38 (61) Ever76 (57)52 (72)24 (39)ECOG performance status0.829 0,1108 (80)57 (80)51 (82) ≥226 (20)15 (20)11 (18)Tumor size, cm0.747 \<367 (50)32 (44)35 (56) ≥367 (50)40 (56)27 (44)Stage1.000 IIIB9 (7)4 (6)5 (8) IV125 (93)68 (94)57 (92)Metastatic organs0.937 0--2106 (80)58 (81)48 (79) ≥328 (20)16 (19)14 (21)Brain metastasis0.776 No95 (71)47 (65)48 (79) Yes39 (29)25 (35)14 (21)Liver metastasis0.641 No112 (84)57 (79)55 (88) Yes22 (16)15 (21)7 (12)*EGFR* subtype-- Exon19 deletion35 (26)--35 (57) L858R mutation25 (18)--25 (47) Other sites2 (1)--2 (3)First-line regimen- Pemetrexed/platinum72 (54)72 (100)- Gefitinib3 (2)-3 (5) Erlotinib4 (3)-4 (6) Afatinib55 (41)-55 (81)SUVmax0.010 Low (\<9.6)40 (30)30 (42)52 (84) High (≥9.6)94 (70)42 (58)10 (16)[^1]

Association Between SUVmax and *EGFR* Mutational Status {#s0003-s2002}
-------------------------------------------------------

The SUVmax was significantly lower in the *EGFR*-mutated group (mean, 6.11 ± 2.77) than in the *EGFR*-negative group (mean, 10.41 ± 5.61, *p* \< 0.001) ([Figure 1A](#f0001){ref-type="fig"}). ROC curve analysis was performed to determine the optimal cutoff for discriminating *EGFR* mutational status. At the cutoff of 9.6, the AUC was 0.760 (95% CI: 0.673--0.833, p \< 0.001), with a sensitivity of 55.6% and a specificity of 89.5% ([Figure 1B](#f0001){ref-type="fig"}). The proportion of tumors with low SUVmax (\< 9.6) was significantly higher in the *EGFR-*mutated group than in the *EGFR* wild-type group (84% vs 42%, *p* = 0.010) ([Table 1](#t0001){ref-type="table"}).Figure 1(**A**) Box plot of SUVmax of the primary tumor. Mean SUVmax was significantly lower in *EGFR*-mutated tumors than in *EGFR* wild-type (6.11 vs 10.41, *p* \< 0.001). Bars indicate 95% confidence interval of mean values. (**B**) The receiver operating characteristic (ROC) curve of SUVmax for discriminating *EGFR* mutational status. At the cutoff of 9.6, the AUC was 0.760 (95% CI: 0.673--0.833, p \< 0.001).

Analysis of Predictive Factors of *EGFR* Mutational Status {#s0003-s2003}
----------------------------------------------------------

In the univariate analysis, the female gender, no history of smoking, and low SUVmax were significantly associated with positive *EGFR* mutation (all p \< 0.05). In the multivariate analysis, the female gender (HR = 2.65, 95% CI: 1.13--5.19), no history of smoking (HR = 1.28, 95% CI: 1.05--4.12), and low SUVmax (HR = 3.14, 95% CI: 1.23--5.57) were independently associated with *EGFR* positivity ([Table 2](#t0002){ref-type="table"}).Table 2Analysis Results for the Variables Associated with *EGFR* Mutational StatusNo. of Patients (%)Univariate AnalysisMultivariate AnalysisOR (95% CI)*p*OR (95% CI)*p*All62 (100)Gender0.0040.014 Female32 (52)2.26 (1.08--4.93)2.65 (1.13--5.19) Male30 (47)ReferenceReferenceAge0.1630.521 \<6528 (45)1.14 (0.78--2.96)1.08 (0.64--2.13) ≥6534 (55)ReferenceReferenceSmoking0.0080.044 Never38 (61)1.82 (1.13--2.17)1.28 (1.05--4.12) Ever24 (39)ReferenceReferenceSUVmax0.0050.017 Low (\<9.6)52 (84)2.26 (1.11--4.25)3.14 (1.23--5.57) High (≥9.6)10 (16)ReferenceReference[^2]

Survival Analysis for the Patients Receiving *EGFR*-TKIs as a First-Line Treatment {#s0003-s2004}
----------------------------------------------------------------------------------

The optimal cutoff values for the survival analysis, as determined by the Log rank test, were 3.54 for SUVmax, 14.08 for MTV~1.5,~ 69.86 for TLG~1.5,~ 4.28 for MTV~2.5~, and 12.64 for TLG~2.5~ ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=259055.pdf)]{.ul}). Survival analysis results on clinical and metabolic parameters are summarized in [Table 3](#t0003){ref-type="table"}. The median PFS for all study subjects was 15.3 months (range, 2.2--30.4 months). The univariate analysis showed metastases in 3 or more organs, gefitinib/erlotinib use, and high SUVmax showed a trend of association with shorter PFS. In addition, smoking, high MTV, and TLG, regardless of SUV cutoffs, were significantly associated with shorter PFS (all *p* \< 0.05). Multivariate analysis showed that smoking (HR = 2.08, 95% CI: 1.02--4.26), MTV~1.5~ (HR = 3.12, 95% CI: 1.35--6.67), TLG~1.5~ (HR = 3.26, 95% CI: 1.45--7.32), MTV~2.5~ (HR = 2.16, 95% CI: 1.05--4.44), and TLG~2.5~ (HR = 2.19, 95% CI: 1.10--4.68) were independently associated with shorter PFS. Kaplan--Meier survival curves showed that patients with high values of metabolic parameters were likely to have poor survival in terms of PFS ([Figure 2](#f0002){ref-type="fig"}).Table 3Survival Analyses Results According to Clinicopathologic and Metabolic Parameters in *EGFR*-Mutated PatientsNo. of Patients (%)Progression-Free Survival (PFS)Overall Survival (OS)Median PFS (Months)Univariate Analysis *p*Multivariate Analysis Adjusted HR (95% CI)Median OS (Months)Univariate Analysis *p*Multivariate Analysis Adjusted HR (95% CI)All62 (100)15.328.5Gender0.1450.091 Female32 (52)17.4Reference34.3Reference Male30 (47)14.11.57 (0.98--3.14)21.01.69 (0.74--2.85)Age, yrs0.1790.252 \<6528 (45)17.9Reference32.4Reference ≥6534 (55)14.21.14 (0.57--2.26)26.31.28 (0.73--1.93)Smoking0.0490.409NA Never38 (61)17.3Reference30.2 Ever24 (39)12.22.08 (1.02--4.26)26.1ECOG performance status0.320NA0.078 0, 151 (82)16.729.9Reference ≥211 (18)13.426.21.08 (0.22--2.74)Stage0.2360.548NA IIIB5 (8)15.6Reference28.3 IV57 (92)13.21.23 (0.56--2.73)24.5Metastatic organs0.0880.011 0--248 (79)17.3Reference31.3Reference ≥314 (21)11.81.98 (0.35--3.14)17.02.11 (1.04--3.61)Brain metastasis0.1990.273 No48 (79)16.3Reference29.5Reference Yes14 (21)14.41.20 (0.35--2.63)27.61.37 (0.65--3.41)Liver metastasis0.362NA0.674NA No55 (88)16.928.6 Yes7 (12)14.429.5*EGFR* subtypes\*0.459NA0.449NA 19del35 (57)15.330.3 L858R25 (47)16.923.3First-line treatment0.0630.316NA Gefitinib/erlotinib22 (35)12.21.82 (0.92--3.56)24.3 Afatinib40 (65)15.8Reference29.3SUVmax0.0570.070 Low (\<3.54)12 (20)16.1Reference32.3Reference High (≥3.54)50 (80)12.41.15 (0.92--3.46)25.91.61 (0.89--3.17)MTV~1.5~0.015 Low (\<14.08)26 (42)20.80.010Reference36.1Reference High (≥14.08)36 (58)13.13.12 (1.35--6.67)24.34.18 (1.28--10.85)TLG~1.5~0.018 Low (\<69.86)31 (50)20.20.008Reference34.9Reference High (≥69.86)31 (50)13.03.26 (1.45--7.32)23.74.62 (1.26--12.11)MTV~2.5~0.0230.036 Low (\<4.28)25 (47)19.8Reference35.5Reference High (≥4.28)37 (53)13.62.16 (1.05--4.44)24.62.04 (1.08--6.25)TLG~2.5~0.0260.041 Low (\<12.64)22 (35)20.1Reference35.6Reference High (≥12.64)40 (65)13.92.19 (1.10--4.68)26.51.87 (1.02--6.33)[^3][^4] Figure 2Kaplan--Meier survival curves for progression-free survival (PFS). (**A**) SUVmax, (**B**) MTV~1.5~, (**C**) TLG~1.5~, (**D**) MTV~2.5~, (**E**) TLG~2.5~. *P*-values were determined using the Log rank test.

The median OS for all study subjects was 28.5 months (range, 2.2--56.0 months). Univariate analysis showed that male sex, poor performance status, and low SUVmax showed a trend of association with OS. Metastases in 3 or more organs and high MTV and TLG, regardless of SUV cutoffs, were significantly associated with shorter OS (all *p* \< 0.05). Multivariate analysis showed that metastases in 3 or more organs (HR = 2.11, 95% CI: 1.04--3.61), MTV~1.5~ (HR = 4.18, 95% CI: 1.28--10.85), TLG~1.5~ (HR = 4.62, 95% CI: 1.26--12.11), MTV~2.5~ (HR = 2.04, 95% CI: 1.08--6.25), and TLG~2.5~ (HR = 1.87, 95% CI: 1.02--6.33) were independently associated with shorter OS. Kaplan--Meier survival curves showed that patients with high values of metabolic parameters were likely to have poor survival in terms of OS ([Figure 3](#f0003){ref-type="fig"}).Figure 3Kaplan--Meier survival curves for overall survival (OS). (**A**) SUVmax, (**B**) MTV~1.5~, (**C**) TLG~1.5~, (**D**) MTV~2.5~, (**E**) TLG~2.5~. *P*-values were determined using the Log rank test.

Representative cases of *EGFR*-mutant patients with different PFS and OS according to different MTV and TLG of the primary tumors are presented in [Figure 4](#f0004){ref-type="fig"}.Figure 4Representative examples of PET/CT images of *EGFR*-mutated patients with different metabolic parameters showing different clinical outcomes. (**A**) A case of a 75-year-old man having a primary tumor in the right upper lobe. MTV~1.5~ is 8.6 and TLG~1.5~ is 14.5. His PFS and OS are 12.6 and 18.7 months, respectively. (**B**) A case of a 76-year-old man having a primary tumor in the right upper lobe. MTV~1.5~ is 22.7 and TLG~1.5~ is 71.8. His PFS and OS are 5.4 months and 9.7 months, respectively.

Discussion {#s0004}
==========

The present data demonstrate that SUVmax is significantly lower in *EGFR*-mutated lung adenocarcinoma than in the *EGFR* wild-type, and low SUVmax (\< 9.6) may be predictive of *EGFR* mutation. In addition, volumetric parameters such as high MTV and TLG measured in the primary tumor were associated with shorter PFS and OS in *EGFR*-mutant patients treated with first-line *EGFR*-TKIs, even after adjusting for the effects of clinical parameters. To the best of our knowledge, this is the first report identifying that ^18^F-FDG PET/CT parameters of primary tumors may have predictive and prognostic values in advanced *EGFR*-mutated lung adenocarcinoma.

Although mutational analysis using tumor tissue or body fluid is the standard method for determining *EGFR* mutational status, it is sometimes limited by issues such as invasiveness of the tissue acquisition procedures and inaccessibility or insufficiency of sample tissues. Thus, metabolic parameters obtained from the ^18^F-FDG PET/CT data have been evaluated for non-invasive predictions of *EGFR* mutation.[@cit0025]--[@cit0028] SUVmax, representing the most active metabolic location of the tumor, is the most studied, and several studies have shown that low SUVmax is associated with *EGFR* mutation.[@cit0026],[@cit0028],[@cit0029] Previous studies have demonstrated that glucose transporter 1 (GLUT1), which serves important functions in glucose transport, may be regulated by reactive oxygen species (ROS).[@cit0030],[@cit0031] Chen et al recently observed that ROS activity was lower in *EGFR*-mutant lung cancer cells than in wild-type cells, and identified the role of NADPH oxidase 4 (NOX4)/ROS/GLUT1 axis in glucose metabolism; downregulated NOX4 expression led to a decrease in ROS activity resulting in decreased GLUT1 expression. The decreased FDG uptake in *EGFR*-mutant cells can partially be explained by this mechanism.[@cit0029] However, the data on the value of SUVmax in predicting *EGFR* mutation are still conflicting, as some studies have failed to prove associations.[@cit0025],[@cit0027],[@cit0032],[@cit0033] One of the reasons for the conflicting results among studies is the differences in the study design and patient characteristics across the studies. All the aforementioned studies enrolled *EGFR*-mutated patients of all clinical stages. Some studies enrolled all NSCLC histologic subtypes,[@cit0025],[@cit0028] while others did not.[@cit0026],[@cit0027],[@cit0033] *EGFR* mutation is dominant in adenocarcinomas, and tumors harboring this mutation become heterogeneous as they progress due to the clonal evolution.[@cit0034],[@cit0035] Thus, their metabolic characteristics could vary with the clinical stages. In addition, the detection of *EGFR* mutation is more important in advanced than in early-stage lung cancer because the presence or absence of the mutation determines treatment strategy; whether TKIs should be used for frontline treatment or not. Thus, we ensured that our population was more homogenous, consisting of advanced *EGFR*-mutated adenocarcinomas, and we successfully demonstrated that SUVmax, even in advanced stages, can predict *EGFR* mutational status at the cutoff of 9.6. Our data are consistent with those from previous studies,[@cit0028],[@cit0036] and they suggest that PET/CT may be a helpful non-invasive modality for predicting *EGFR* mutation. Our results should be validated and the optimal cutoff should be determined in further large-scale investigations. In addition, the clinical significance of other metabolic parameters as predictors for *EGFR* mutations need to be evaluated, as a recent study has demonstrated that MTV could discriminate the *EGFR*-positive patients from those without the mutation.[@cit0037]

In contrast to SUV, which reflects the high metabolic lesion of the tumor, MTV and TLG incorporate metabolic burden and disease extent, and they may have better predictive values than SUV. Several studies have demonstrated that volumetric parameters have prognostic values in advanced NSCLC treated with chemotherapy.[@cit0012],[@cit0016],[@cit0017] However, the clinical significance of those parameters in *EGFR*-mutated patients receiving TKIs may differ in wild-type patients treated with chemotherapy since the mechanism by which TKIs induce cancer cell death is different from that of cytotoxic agents. In addition, tumors with *EGFR* mutations are metabolically indolent, as shown in previous studies and our present study. To date, only 3 studies have investigated the predictive value of the various metabolic parameters in advanced *EGFR*-mutated NSCLC.[@cit0011],[@cit0038],[@cit0039] We have summarized their results in [Table 4](#t0004){ref-type="table"}. One study reported that high SUVmax (\> 12) was independently associated with PFS.[@cit0038] Other studies reported that high whole-body TLG was significantly associated with poor survival in patients treated with *EGFR*-TKIs.[@cit0011],[@cit0039] However, the latter two studies evaluated MTV and TLG from whole-body lesions.Table 4Summary of Published Data and the Present Study on the Association Between ^18^F-FDG PET/CT Metabolic Parameters and Clinical Outcome of Advanced *EGFR*-Mutated Lung AdenocarcinomaAuthor, YearPathologyNo. of PatientsMetabolic Parameters AnalyzedResultsTKIs UsedKeam et al,[@cit0036] 2015ADC, NSCC NOS75SUVmax and TLG of all lesionsHigh whole-body TLG (third quartile) is significantly associated with PFS and OS.GefitinibWang et al,[@cit0011] 2016ADC91SUVmax and TLG of the primary tumor and target lesions\*High whole-body TLG of (\>260) is significantly associated with PFS but not OS.GefitinibSing et al,[@cit0035] 2020ADC41SUVmaxHigh SUVmax (\>12) independently associated with PFS.Erlotinib, GefitinibPresent studyADC60SUVmax, MTV, and TLG of the primary tumorHigh TLG and MTV of the primary tumor were independently associated with PFS and OS.Gefintib, Erlotinib,\
Afatinib[^5][^6]

Although it may be ideal to calculate whole-body volumetric information to ascertain the exact metabolic tumor burden, it is time-consuming, especially in patients with extensive metastasis; thus, it may be impractical despite its proven significance. We aimed at finding simpler, image-based markers that could be readily used in clinical practice, and hypothesized that volumetric parameters of the primary tumor have prognostic values. To determine the best parameters, we used two SUV cutoffs to calculate MTV and TLG. The present data showed that high MTV and TLG, regardless of the SUV cutoffs, were independently associated with poor PFS and OS. The HRs of MTV~1.5~ (3.12 for PFS and 4.18 for OS) and TLG~1.5~ (3.26 for PFS and 4.62 for OS) were higher than those of MTV~2.5~ (2.16 for PFS and 2.04 for OS) and TLG~2.5~ (2.19 for PFS and 1.89 for OS), suggesting that the predictive performance of volumetric parameters may be better at the cutoff SUV of 1.5 than 2.5. The exact reason for the better performance of the volumetric parameters with low SUV cutoff is not clear; however, we postulate that the low cutoff permits an MTV that is reflective of a more exact metabolic burden of primary tumors compared with a high cutoff because *EGFR-*mutant tumors are metabolically indolent.[@cit0026],[@cit0028],[@cit0029] Our results are supported by a previous report demonstrating that MTV and TLG of the primary tumor, rather than SUVmax, were associated with clinical outcomes in NSCLC patients treated with chemotherapy.[@cit0012]

Although SUV has been extensively studied and was proven to be related with prognosis in NSCLC patients across all stages, it has several limitations as an optimal metabolic parameter; it depends on various patient-related (body size, blood glucose levels) and technical (reconstruction method, partial volume effect) factors,[@cit0040] and does not account for tumor volume, which can be related to the T descriptor in the staging system that is associated with prognosis. Especially, SUVmax is the value of a single voxel in the region of interest that is subject to statistical variability due to noise in a reconstructed PET/CT image.[@cit0015] The clinical usefulness of volumetric parameters and optimal SUV cutoffs in calculating metabolic tumor burden should be validated in large-scale studies.

This study has several limitations. First, it is a retrospective study and selection bias is inevitable. Second, it was performed in a single institution and the sample size was small. To compensate for the small sample size and to collect relevant data, we analyzed various metabolic parameters at the various SUV cutoffs simultaneously, and two nuclear medicine specialists assessed the PET/CT images. Third, patients with other genetic alterations such as *ROS1* and *ALK* fusion were not assessed because of the rarity of the alterations among lung adenocarcinoma patients (1%-5%). Finally, we focused on the baseline metabolic parameters rather than follow-up data after treatment. As suggested in a study on NSCLC patients treated with concurrent chemoradiation, the change in metabolic parameters from the baseline to the subsequent study may also have valuable clinical implications.[@cit0041]

Conclusion {#s0005}
==========

In conclusion, SUVmax may be useful in predicting *EGFR* mutational status, while MTV and TLG, measured in the primary tumor, may be useful for predicting treatment response and survival in lung adenocarcinomas treated with TKIs. Our results highlight a practical, image-based method for the discrimination of *EGFR-*mutated tumors from wild-types and risk stratification before TKI use. If large-scale prospective studies confirm our results, PET/CT metabolic parameters, either alone or combined with other clinical parameters, can be used to select patients with TKI resistance and modify treatment strategy or prompt more rigorous follow-up. Our data also suggest the possible application of the parameters in other clinical settings, such as immunotherapy, which may facilitate the clinical utilization of PET/CT as a non-invasive predictive and prognostic modality in lung cancer management.

This research was supported by a grant from the Basic Research Program through the National Research Foundation funded by the Ministry of Science and ICT (2019R1F1A1041812) of the Republic of Korea.

Disclosure {#s0006}
==========

The authors declare that they have no competing interests.

[^1]: **Abbreviations:** ECOG, Eastern Cooperative Oncology Group; *EGFR*, epidermal growth factor receptor; SUVmax, maximal standardized uptake value.

[^2]: **Abbreviations:** SUVmax, maximal standardized uptake value; OR, odds ratio; CI, confidence interval.

[^3]: **Note:** \*Two patients harboring rare mutation were excluded.

[^4]: **Abbreviations:** ECOG, Eastern Cooperative Oncology Group; *EGFR*, epidermal growth factor receptor; SUV, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; HR, hazard ratio; CI, confidence interval; NA, not applicable.

[^5]: **Note:** \*Target lesions were selected in accordance with the RECIST 1.1 criteria.

[^6]: **Abbreviations:** TKIs, tyrosine kinase inhibitors; ADC, adenocarcinoma; NSCC NOS, non-small-cell carcinoma not otherwise specified, SUV, standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; PFS, progression-free survival; OS, overall survival.
